Medicine and Dentistry
Fitness
100%
Sofosbuvir
90%
Hepatitis C Virus
54%
Resistance Mutation
36%
Biological Product
18%
Drug Sensitivity
18%
Hepatitis C
9%
Combination Therapy
9%
Antivirus Agent
9%
Polymerase
9%
Chemotherapeutic Agent
9%
Hepatoma Cell
9%
Daclatasvir
9%
Virus Inhibition
9%
Telaprevir
9%
Hepacivirus
9%
Drug
9%
Therapeutic Procedure
9%
Child
9%
Immunology and Microbiology
Fitness
100%
Sofosbuvir
90%
Hepatitis C Virus
63%
Mutation
36%
Clone
27%
Biological Product
18%
NS5B
18%
Drug Sensitivity
18%
Progeny
9%
Hepatoma Cell
9%
Virus Inhibition
9%
Daclatasvir
9%
Telaprevir
9%
Hepacivirus
9%
Viral Disease
9%
Pharmacology, Toxicology and Pharmaceutical Science
Fitness
100%
Sofosbuvir
90%
Hepatitis C Virus
54%
Biological Product
18%
Hepatitis C
9%
Combination Therapy
9%
Antivirus Agent
9%
Daclatasvir
9%
Telaprevir
9%
Drug
9%
Hepacivirus
9%
Virus
9%
Neuroscience
Sofosbuvir
90%
Hepatitis C Virus
63%
NS5B
18%
In Vivo
9%
Antivirals
9%
Coding Region
9%
Telaprevir
9%
Polymerase
9%
Daclatasvir
9%
Biochemistry, Genetics and Molecular Biology